Patents by Inventor Tom Humphreys

Tom Humphreys has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120065371
    Abstract: Filovirus subunit protein immunogens are produced using a recombinant expression system and combined with one or more adjuvants in immunogenic formulations. The subunit proteins include GP95, GP-FL, VP40, VP24, and NP derived from Ebola Virus and Marburg Virus. Adjuvants include saponins, emulsions, alum, and dipeptidyl peptidase inhibitors. The disclosed immunogenic formulations are effective in inducing strong antibody responses directed against individual Filovirus proteins and intact Filovirus particles as well as stimulating cell-mediated immune responses to the Filoviruses.
    Type: Application
    Filed: April 4, 2011
    Publication date: March 15, 2012
    Applicant: PanThera Biopharma LLC
    Inventors: Axel Thomas Lehrer, David E. Clements, Tom Humphreys
  • Patent number: 7947286
    Abstract: Filovirus subunit protein immunogens are produced using a recombinant expression system and combined with one or more adjuvants in immunogenic formulations. The subunit proteins include GP95, GP-FL, VP40, VP24, and NP derived from Ebola Virus and Marburg Virus. Adjuvants include saponins, emulsions, alum, and dipeptidyl peptidase inhibitors. The disclosed immunogenic formulations are effective in inducing strong antibody responses directed against individual Filovirus proteins and intact Filovirus particles as well as stimulating cell-mediated immune responses to the Filoviruses.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: May 24, 2011
    Assignee: PanThera Biopharma LLC
    Inventors: Axel Thomas Lehrer, David Edward Clements, Tom Humphreys
  • Publication number: 20080213318
    Abstract: A vaccine or immunogenic composition is described that contains recombinantly produced, secreted, forms of malaria MSP-1 C-terminal subunit proteins from any of the Plasmodium falciparum strains as active ingredients combined with one or more adjuvants. The immunogenic compositions that result in a protective response are based on the use of a single adjuvant that forms an emulsion or use of such emulsion in combination with a second adjuvant that is an immunomodulating agent. Such a vaccine elicits a strong immune response characterized by antibodies that are capable of inhibiting parasite growth in vitro as well as antibodies that are incapable of inhibiting parasite growth in vitro, but are capable of enhancing the activity of the inhibitory antibodies. The disclosed vaccine formulations are capable of generating a protective response against malaria in vaccinated subjects.
    Type: Application
    Filed: July 3, 2006
    Publication date: September 4, 2008
    Inventors: David E. Clements, Tom Humphreys
  • Publication number: 20070082011
    Abstract: Filovirus subunit protein immunogens are produced using a recombinant expression system and combined with one or more adjuvants in immunogenic formulations. The subunit proteins include GP95, GP-FL, VP40, VP24, and NP derived from Ebola Virus and Marburg Virus. Adjuvants include saponins, emulsions, alum, and dipeptidyl peptidase inhibitors. The disclosed immunogenic formulations are effective in inducing strong antibody responses directed against individual Filovirus proteins and intact Filovirus particles as well as stimulating cell-mediated immune responses to the Filoviruses.
    Type: Application
    Filed: October 5, 2006
    Publication date: April 12, 2007
    Inventors: Axel Lehrer, David Clements, Tom Humphreys
  • Publication number: 20050287170
    Abstract: An immunogenic composition is described that preferably contains a recombinantly produced form of truncated West Nile envelope glycoprotein and one or more adjuvants acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent populations. The disclosed immunogenic compositions can further comprise a recombinantly produced non-structural (non-envelope) West Nile protein. An adjuvant typically comprises a saponin, saponin-based adjuvant (e.g., ISCOMATRIX® or GPI-0100), emulsion-based adjuvant (e.g., Co-Vaccine HT), or alum-based adjuvant. A pharmaceutically acceptable vehicle may also be included in the immunogenic composition.
    Type: Application
    Filed: April 25, 2005
    Publication date: December 29, 2005
    Inventors: Michael Lieberman, Tom Humphreys
  • Publication number: 20040213808
    Abstract: An immunogenic composition is described which preferably contains recombinantly produced forms of truncated flavivirus envelope glycoproteins and an adjuvant. The disclosed immunogenic compositions can further comprise a recombinantly produced non-structural (non-envelope) flavivirus protein. The adjuvant typically comprises a saponin preferably derived from the Quillaja saponica tree or a derivative thereof. The adjuvant can also comprise an oligodeoxyribonucleotide preferably containing specific sequences of nucleotides described herein. A pharmaceutically acceptable vehicle may also be included in the immunogenic composition.
    Type: Application
    Filed: December 8, 2003
    Publication date: October 28, 2004
    Inventors: Michael Lieberman, Tom Humphreys
  • Patent number: 6682909
    Abstract: The present invention provides truncated HCV E2 polypepides. The invention HCV E2 polypeptides lack the HVR1 region that provides immune protection against HCV. The present invention also provides immunogenic compositions of such polypeptides and the methods of use thereof.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: January 27, 2004
    Assignee: Hawaii Biotech, Inc.
    Inventors: Eileen T. Nakano, David E. Clements, Tom Humphreys
  • Publication number: 20020119495
    Abstract: The present invention provides truncated HCV E2 polypepides. The invention HCV E2 polypeptides lack the HVR1 region that provides immune protection against HCV. The present invention also provides immunogenic compositions of such polypeptides and the methods of use thereof.
    Type: Application
    Filed: September 13, 2001
    Publication date: August 29, 2002
    Inventors: Eileen T. Nakano, David E. Clements, Tom Humphreys